skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8119

Safety and efficacy of azacitidine in myelodysplastic syndromes

Review

(2149) Views  (781) Full article downloads

Authors: Carlos E Vigil, Taida Martin-Santos, Guillermo Garcia-Manero

Published Date September 2010 Volume 2010:4 Pages 221 - 229
DOI: http://dx.doi.org/10.2147/DDDT.S3143

Carlos E Vigil, Taida Martin-Santos, Guillermo Garcia-Manero
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Purpose: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed.
Summary: Azacitidine is the first drug FDA-approved for the treatment of myelodysplastic syndromes that has demonstrated improvements in overall survival and delaying time to progression to acute myelogenous leukemia. The recommended dosage of azacitidine is 75 mg/m2 daily for 7 days, with different treatment schedules validated. It appears to be well tolerated, with the most common adverse effects being myelosuppression. Several other off-label recommendations were also analyzed.
Conclusion: Azacitidine is the first DNA hypomethylating agent approved by FDA for the treatment of myelodysplastic syndromes with demonstrated efficacy.

Keywords: Azacitidine, MDS, hypomethylating agents




  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University